Sodium nitroprusside, a nitric oxide donor for novel treatment of schizophrenia, may also modulate dopaminergic systems

Schizophrenia Research

Volumn 159, Issue 2-3, 2014, Pages 558-559

  Maia de Oliveira, Joao Paulo ^a   Lobão Soares, Bruno ^b   Baker, Glen B ^c   Dursun, Serdar M ^c   Hallak, Jaime E C ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b FEDERAL UNIVERSITY OF RIO GRANDE DO NORTE   (Brazil)

^c UNIVERSITY OF ALBERTA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIC GMP; DOPAMINE; DOPAMINE TRANSPORTER; GLUTAMIC ACID; N METHYL DEXTRO ASPARTIC ACID; NEUROLEPTIC AGENT; NITRIC OXIDE; NITRIC OXIDE DONOR; NITROPRUSSIDE SODIUM; RISPERIDONE;

DOPAMINERGIC SYSTEM; HUMAN; LETTER; NEUROMODULATION; NEUROTRANSMISSION; NONHUMAN; PREPULSE INHIBITION; SCHIZOPHRENIA; SIGNAL TRANSDUCTION; SLEEP WAKING CYCLE;

EID: 84922434925     PISSN: 09209964     EISSN: 15732509     Source Type: Journal    
DOI: 10.1016/j.schres.2014.08.020     Document Type: Letter

References (12)

1. Bujas-Bobanovic M., Bird D.C., Robertson H.A., Dursun S.M. Blockade of phencyclidine-induced effects by a nitric oxide donor. Br. J. Pharmacol. 2000, 409:57-65.
2. Coyle J.T. NMDA receptor and schizophrenia: a brief history. Schizophr. Bull. 2012, 38(5):920-926.
3. Dzirasa K., Ribeiro S., Costa R., Santos L.M., Lin S.C., Grosmark A., Sotnikova T.D., Gainetdinov R.R., Caron M.G., Nicolelis M.A. Dopaminergic control of sleep-wake states. J. Neurosci. 2006, 26(41):10577-10589.
4. Ebstein R.P., Biederman J., Rimon R., Zohar J., Belmaker R.J. Cyclic GMP in the CSF of patients with schizophrenia before and after neuroleptic treatment. Psychopharmacology 1976, 51:71-74.
5. Editors Where next with psychiatric illness?. Nature 1988, 336:95-96.
6. Hallak J.E., Maia-de-Oliveira J.P., Abrao J., Evora P.R., Zuardi A.W., Crippa J.A., Belmonte-de-Abreu P., Baker G.B., Dursun S.M. Rapid improvement of acute schizophrenia symptoms after intravenous sodium nitroprusside: a randomized, double-blind, placebo-controlled trial. JAMA Psychiatry 2013, 70(7):668-676.
7. Issy A.C., Pedrazzi J.F., Yoneyama B.H., Del-Bel E.A. Critical role of nitric oxide in the modulation of prepulse inhibition in Swiss mice. Psychopharmacology (Berlin) 2014, 231(4):663-672.
8. Lee B.H., Kim Y.K. Reduced plasma nitric oxide metabolites before and after antipsychotic treatment in patients with schizophrenia compared to controls. Schizophr. Res. 2008, 104:36-43.
9. Maia-de-Oliveira J.P., Trzesniak C., Oliveira I.R., Kempton M.J., Rezende T.M., Iego S., Baker G.B., Dursun S.M., Machado-de-Sousa J.P., Hallak J.E. Nitric oxide plasma/serum levels in patients with schizophrenia: a systematic review and meta-analysis. Rev. Bras. Psiquiatr. 2012, 34:S149-S162.
10. Oliveira J.P., Machado-de-Sousa J.P., Baker G.B., Dursun S., Hallak J.E. Targeting the NMDA receptor-nitric oxide-cyclic GMP pathway to develop non-dopaminergic antipsychotic medications for schizophrenia. Rev. Bras. Psiquitr. 2011, 33:223.
11. Pycock C.J., Kerwin R.W., Carter C.J. Effect of lesion of cortical dopamine terminals on subcortical dopamine receptors in rats. Nature 1980, 286:74-76.
12. Seeman P. Schizophrenia and dopamine receptors. Eur. Neuropsychopharmacol. 2013, 23(9):999-1009.